Evidence map›Paper›PMID 31564201›Full record

ArticleCell cycle (Georgetown, Tex.)2019

Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.

Wei Song, Jingjing Zhang, Qingxin Xia, Miaomiao Sun

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Making Sense of Antisense lncRNAs in Hepatocellular Carcinoma.International journal of molecular sciences · 2023
    Review
  4. [Overexpression of miR-607 inhibits hepatocellular carcinoma cell growth and metastasis by down-regulating TRPC5].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wei SongDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan , PR China.
Jingjing ZhangDepartment of Cardiovascularology, The Zhengzhou Central Hospital Affiliated to Zhengzhou University , Zhengzhou , Henan , PR China.
Qingxin XiaDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan , PR China.
Miaomiao SunDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan , PR China.ORCID https://orcid.org/0000-0002-7338-4522
Zhengzhou University · CNZhengzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAnimalsApoptosisCarcinoma, HepatocellularCell Line, TumorCell ProliferationCell SurvivalDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiceMice, Inbred BALB CMice, NudeAKT1 protein, humanProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanRNA, Long NoncodingRNA, Small InterferingapoptosisHepatocellular carcinomalong non-coding RNA TP73-AS1proliferationPTEN/Akt signaling pathwayradioresistance

Identifiers

PMID31564201
PMCPMC6816373
OpenAlexW2978677526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.